Method for treating the cases of allergic diseases

FIELD: medicine.

SUBSTANCE: method involves introducing autologic mesenchyma trunk cells as a single intravenous drop dose or in the amount of 1 mln cells per 1 kg of patient body weight.

EFFECT: provided stable clinical remission.

 

The invention relates to medicine, more specifically to Allergology and immunology, and may find application in the treatment of allergic diseases of various origins.

Allergic diseases at the present time, according to who, suffering from not less than 30% of the population. It is associated with adverse environmental, technological and other factors. Total Allergy not only in itself causes huge financial losses, but also inevitably leads to aggravation of other diseases, and also worsens their prognosis.

The treatment of allergic diseases currently present a serious problem. Modern medicine has a significant Arsenal of drugs and treatment regimens for skin allergies (Duhatschek, Dlling. Secrets of dermatology // TRANS. from English. - M.; SPb.: Publisher BINOM Nevsky dialect, 1999. - P.57-156, S-418, S-468), as well as drugs for systemic exposure (Reference therapist / edited Fionaluv. - M.: Medicine, 1979, 656 S.; Handbook of General practitioner /Neprochnov, Vaasana etc. // ed Nuraliev. - M.: EKSMO-Press, 2001. - T.1 - c.306-322). However, more than half of the patients the effect of the application of any scheme of medical treatment is incomplete and short-lived.

Closest to the proposed method is a method lectually diseases through the application of a combination of mixed drugs (Handbook of General practitioner. // Edited Nuraliev. - M.: EKSMO-Press. - 2001. - T.1.- C.306-322).

The method consists in carrying out specific and nonspecific desensitization.

Specific desensitization is subcutaneous injection of identified allergens in low titers after chemical modification. Disadvantages of the method are the duration of treatment and a large number of injections. In the introduction of the allergen can be painful infiltrates, possible systemic reactions (urticaria, asthma, exacerbation of chronic infections). In severe somatic diseases, pregnancy, rheumatism, tuberculosis, malignant tumors, gastric ulcer and other diseases such treatment is contraindicated because it causes aggravation of the disease. More than half of the patients suffering from allergies, search specific antigen is unsuccessful, and some antigens do not exist in the modified dosage forms.

Nonspecific desensitization with severe allergies is carried out in two stages. At the first stage for the relief of acute manifestations of Allergy are forcing diuresis (intravenous drip 1500-2000 ml of physiological solution, at the end of infusion 40 mg of latexa intravenously or intramuscularly); stimulate peristalsis (25% solution MAGN what Ziya inside). In the second stage, which lasts until clinical effect (7-12 days), prescribed drugs calcium (10% solution of calcium chloride - 1 times a day intravenously); chelators (polifan a tablespoon 3 times a day), antihistamines (suprastin 1 tablet 3 times a day or Telfast 1 tablet 1 time per day). In severe cases, the treatment is supplemented by the introduction of prednisolone 90 mg per day. The disadvantages of this treatment are: incomplete and short-lived effect, the need for long courses of treatment, a gradual reduction in efficiency and the consequent need to increase doses, negative effects on many organs and systems, eg, severe chronic diseases, pregnancy, malignancy, glucocorticoid hormones (prednisolone) is contraindicated.

The technical result of the present invention is to reduce the manifestations of allergic diseases and improve patients ' quality of life through the use of autologous mesenchymal stem cells (AMSC).

This result is achieved by the fact that in the treatment of allergies according to the invention once the patient intravenously injected isolated from biopsies his bone marrow was ASK in the amount of 1 million cells per 1 kg of body weight of the patient.

AMSC in recent years started is to use when treating patients with cardiac pathology to improve tissue regeneration (Handbook of Cardiovascular Cell Transplantation.- Ed. N.M.Kipstidze et al.- 2004. - 425 p.).

ASK is the fraction of highly purified autologous stem cells. To obtain AMSC you want to take 20-35 ml bone marrow (the procedure is performed under local short-term intravenous anesthesia and lasts 10-15 min). In a further fraction of AMSC stands out from the bone marrow, thepirouette and grown in a special medium. After 10-12 days from the start of culturing, the number of AMSC reaches 80-100 million, which is ten times higher than the content in the bone marrow. Back introduction AMSC is safe (own cells, there is no risk of allergic reactions), the number of input cells allows to receive the expressed clinical effect.

To use ASK in the treatment RMP us prompted the observation of patients admitted to the clinic in cnerry with a diagnosis of Coronary heart disease. Angina and rest of the 3-rd functional class. Ateroskleroticeski and postinfarction cardiosclerosis (myocardial infarction 1994, 1995, 2004). Status after coronary artery bypass grafting (1996). Circulatory insufficiency II.

In addition to cardiac pathology in the patient there was a strong food paillere, which began about 12 years ago. Allergies were called different, often unknown food, and there was a drain in the papular SIP is, occupying the skin of the chest, back and forearms. The patient is constantly took suprastin, periodically - prednisolone.

The goal of entering the patient was koronaroangiografii (CAT) to assess the condition of the vessels of the heart and treatment. When performing coronary angiography was planned the introduction of intracoronary ASK to improve cardiac muscle performance. For this one month prior to this admission, the patient was taken 30 ml of bone marrow and cultured 100 million ASK.

However, the CAG was associated with a high risk of increased allergic reactions in response to the injection of a contrast agent. It was therefore decided to limit intravenous drip was AMSC dose of 76 million (1 million cells per 1 kg of patient's body weight), which was completed in April 2004

Totally unexpected effect from the introduction of OMSK was the reduction of skin allergies, which began on the 5th day after injection. Two weeks later, skin rash completely disappeared, and the patient was able to refuse the acceptance of anti-allergic drugs, which he used for many years in continuous mode.

In June 2004, the patient underwent a CAT that he had no adverse reactions and complications.

Allergies the patient has to date not available, it eats a variety of food, including the KJV is rebleed products and juices, previously inevitably caused a pronounced skin rash. Such persistent anti-allergic effect of AMSC allowed us to apply further transplantation ASK patients with severe allergies.

The essence of the method is illustrated by examples.

Example 1. Patient M., 59 years old, medical history, No. 814, received 17. 05. 2004 in the Department of new technologies in radiotherapy clinic cnerry health Ministry. Sick for 20 years, suffering from food allergies, which is expressed by a rash on the face, chest and back, accompanied by itching. Upon admission of the patient to the clinic he observed significant the Allergy symptoms in the form of papular rash all over the body, itching, runny nose, worsened his General condition and substantially disrupts sleep.

To relieve allergic reactions was proposed biotransplant his bone marrow.

For this 25.05.2004 the patient was made fence 30 ml of own bone marrow and grown culture was ASK and 08.06.2004 78 million AMSC (1 million cells per kg of body weight) were introduced to the patient intravenously in 50 ml of culture suspension. Introduction the patient underwent without reactions and complications. 12 million was AMSC were placed in a cryo-Depositary for possible future use.

7 days after the introduction of AMSC allergic skin manifestations in a patient stopped, which allowed to hold him further Leche is the concomitant diseases of the cardiovascular system. Despite taking quite a large number of drugs, the patient was not observed any allergic manifestations, whereas previously he almost couldn't drink any tablets without additional intake of antihistamines.

Up to the present time the condition and the patient's health is satisfactory. The patient offered when he has an allergic reaction at any time of the year, immediately contact the Institute for the relief of its introduction ASK stored in a cryo-Depositary institution.

Example 2. Patient K., aged 63, case history No. 517, received 16.02.2004 in the Department of new technologies in radiotherapy clinic cnerry MH RF, where the survey diagnosed perekhodnocletocny urinary bladder carcinoma T2N0M0. Among opportunistic diseases - ischemic heart disease, myocardial infarction in 1999, circulatory failure, 2nd degree, and hay fever. Sick for 15 years suffered from severe allergies (“hay fever”) with the annual spring exacerbations. Since allergic reactions (March - April) the patient within 2-3 months took large doses of antihistamines (suprastin, tavegil) and glucocorticoid (prednisone, dexamethasone) drugs. On the background of the treatment of Allergy (skin rash, shortness of breath, runny nose, ISU is Remy skin) decreased, but never fully disappeared.

In connection with severe concomitant diseases (severe cardiac pathology, and also strong allergic history) were contraindications for surgical and chemotherapeutic treatment. Therefore, the only treatment for this patient was to undergo radiation therapy after removal of allergies by introducing him to ASK. The patient was offered biotransplant own bone marrow.

To do this, prior to treatment the patient was made fence 25 ml of own bone marrow and grown culture was ASK. 19.03.2004 72 million was ASK (1 million cells per kg of body weight) were introduced to the patient intravenously in 50 ml of culture suspension. Introduction the patient underwent without reactions and complications. 12 million was AMSC were placed in a cryo-Depositary for possible future use.

With 26.02.2004, started a course of radiation therapy, in standard mode, up to a total focal dose of 68 Gy.

A course of radiation treatment was completed in mid-April, when the patient annually for symptoms of hay fever. This year for the first time in 15 years on the background of the treatment of allergies was not. To date, the patient's condition remains stable.

To date, the proposed method, the treatment of three patients with a positive effect. Received the initial effect remain with them until the present time.

The method of treatment of allergic diseases through the use of medical means, characterized in that as a remedy using autologous mesenchymal stem cells are administered once intravenously in the amount of 1 million cells per 1 kg of body weight of the patient.



 

Same patents:

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of indolylpiperidine of the formula (I): wherein A1 means (C1-C7)-alkylene, (C1-C7)-alkyleneoxy-, (C1-C7)-alkylenethio-, (C1-C7)-alkanoyl, hydroxy-(C1-C7)-alkylene; A2 means a single bond, (C1-C7)-alkylene, (C2-C5)-alkenylene; W means a single bond, phenylene, furanylene that is unsubstituted or substituted with one or more halogen atoms, (C1-C7)-alkoxy- and/or alkyl groups; R1 means hydrogen atom (H), (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C2-C5)-alkoxyalkyl, (C3-C7)-alkenyloxyalkyl, (C3-C7)-alkynyloxyalkyl, (C3-C7)-alkoxyalkoxyalkyl, phenyl-(C1-C7)-alkyl wherein phenyl is unsubstituted or substituted with one or more halogen atoms, (C1-C7)-alkyl, (C1-C7)-alkoxy- or arylalkoxy- (preferably with phenylalkoxy-) groups, or means (C3-C10)-cycloalkyl-(C1-C7)-alkyl wherein cycloalkyl is unsubstituted or substituted with one or more halogen atoms, (C1-C7)-alkyl, (C1-C7)-alkoxy-groups; R2 means hydrogen atom (H), halogen atom, (C1-C7)-alkyl, (C1-C7)-alkoxy-; R3 means carboxyl, tetrazolyl, and to their pharmaceutically acceptable salts. Compounds of the formula (I) elicit antihistaminic and anti-allergic activity that allows their using in composition used for treatment of allergic diseases including bronchial asthma, rhinitis, conjunctivitis, dermatitis and nettle rash. Also, invention describes methods for preparing compounds of the formula (I).

EFFECT: valuable medicinal properties of compounds.

15 cl, 2 sch, 3 tbl, 162 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to a new complex of N,N-diethyldithiocarbamate with 2-ethyl-6-methyl-3-hydroxypyridine of the formula: . This complex elicits an anti-allergic activity that allows it using for carrying out the pharmacological control of allergic response based on inhibition of function of allergy target-cells.

EFFECT: valuable medicinal properties of complex.

1 cl, 1 tbl, 3 ex

FIELD: organic chemistry, chemical technology, pharmacy.

SUBSTANCE: invention relates to new spiroimidazolidine derivatives of the formula (1):

wherein R1 represents hydrogen atom or methyl; R2 represents phenyl or (C1-C4)-alkyl; X represents -CH2-CH2- or -CH2-CH2-CH2-; W represents isopropyl or cyclopropyl; V represents hydrogen atom or methoxy-group; E represents -CO-R3 wherein R3 represents hydroxy-group, (C1-C4)-alkoxy- or amino-group; phenyl represents unsubstituted phenyl residue or phenyl residue substituted with one or some similar or different substitutes taken among the group consisting of (C1-C4)-alkoxy-, methylenedioxy- and ethylenedioxy-group in all its stereoisomeric forms and their mixtures in all ratios, and to its physiologically acceptablesalts. Also, invention relates to a method for preparing compounds of the formula (1) and pharmaceutical composition based on these compounds. Invention provides preparing new compounds eliciting the inhibitory effect with respect o leukocytes adhesion.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

16 cl, 1 tbl, 41 ex

FIELD: medicine, immunology, nucleic acids.

SUBSTANCE: invention relates to a method for stimulation of the immune response using nucleic acids-containing immunostimulating compositions, oligonucleotide-containing composition and to a method for treatment or prophylaxis of allergy or asthma. For stimulation of the immune response thymidine-enriched nucleic acid comprising poly-T sequences and/or comprising above 60% of thymidine-containing nucleotide residues is administrated. Invention provides the development of new method for stimulation of the immune response due to administration of the proposed immunostimulating nucleic acid.

EFFECT: valuable medicinal properties of nucleic acid.

27 cl, 12 dwg, 12 ex

The invention relates to medicine, specifically to pharmacology

The invention relates to pharmaceutical
The invention relates to medicine, in particular to Pediatrics, Allergology and pulmonology

The invention relates to the field of medicine and relates to a spontaneously dispersible pharmaceutical composition for oral administration comprising (2R,4S)-N-(1 -(3,5-bis(trifluoromethyl)benzoyl)-2-(4-Chlorobenzyl)-4-piperidinyl)quinoline-4-carboxamide as an antagonist of substance P and the carrier medium containing a hydrophilic component and a surfactant, and methods of treatment using the composition of CNS disorders, including depression and fear of society, and respiratory diseases, such as asthma and chronic bronchitis

The invention relates to new compounds of General formula

which have the properties of receptor antagonists neirokinina-1(NK-1)

FIELD: medicine.

SUBSTANCE: method involves using mononuclear autologic marrow fraction containing 6-9x104 mesenchyma cells per 1 ml or autologic mesenchyma trunk cells. The cells are separated from brain bioptate in the amount of 106 cells/kg of patient body mass. The preparations are intracoronarily introduced in fractions at a rate of 3-5 ml/min into the right coronary artery. The introduction is also carried out in intra-arterial mode in jets or in drops.

EFFECT: higher survival rate and life quality of cardiologic patients.

1 dwg

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

The invention relates to medicine, namely to psychiatry and pharmacotherapy of borderline mental disorders
The invention relates to the technology of obtaining biologically active compounds to increase the resistance of the organism of animals

The invention relates to medicine, namely to methods of producing biologically active preparations from bone marrow of animals

The invention relates to medicine, namely to Oncology, and can be used for the treatment of patients with malignant tumors of the organs of the oral cavity and pharynx
The invention relates to medicine, and is intended for the treatment of peritonitis

The invention relates to medicine, namely to Oncology, and can be used to treat cancer of the larynx

The invention relates to medicine, namely to Oncology, and can be used in cancer chemotherapy breast cancer stage III-IV

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

Up!